Global Pharmaceutical Contract Development and Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Market Size, Share, Growth Analysis, By Service(Pharmaceutical Manufacture, Drug Development, And Biologics Manufacturing.), By End user(Large pharmaceutical firms, small & mid-size pharmaceutical companies, and generic pharmaceutical companies.), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35J2034 | Region: Global | Published Date: July, 2024
Pages: 242 | Tables: 63 | Figures: 75

Pharmaceutical Contract Development and Manufacturing Market News

  • In February 2022, Recipharm AB (Sweden) acquired Arranta Bio (U.S.) to add scientifically differentiated contract development and manufacturing services for ATMPs in its service offerings and develop a strong presence in the U.S.
  • In February 2021, Charles River Laboratories International, Inc. (U.S.) acquired Cognate BioServices, Inc. (U.S.) for $875 million to add cell and gene therapy CDMO capabilities.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 114.36 billion in 2019 and is poised to grow from USD 122.25 billion in 2023 to USD 222.87 billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

To improve their market position, players in the industry are concentrating on agreements, partnerships, collaborations, acquisitions, and other tactics. Pharma firms must provide more and better new pharmaceuticals to combat the diseases to which the human body is susceptible in order to combat the rising number of new diseases. 'Catalent', 'Patheon', ' Lonza Group AG   ', ' Thermo Fisher Scientific, Inc.   ', ' Boehringer Ingelheim GmbH   ', ' Evonik Industries AG   ', ' Recipharm AB   ', ' Vetter Pharma International GmbH   ', ' WuXi AppTec Co. Ltd.   ', ' Famar Health Care Services   ', ' Almac Group   ', ' Jubilant Life Sciences Limited   ', ' Samsung BioLogics   ', ' PRA Health Sciences   ', ' Cambrex Corporation   ', ' Ajinomoto Bio-Pharma Services   ', ' Syneos Health   ', ' Mylan N.V.   ', ' AMRI Global   ', ' Baxter BioPharma Solutions '

The market is being driven by the advantages of outsourcing, namely the savings in time and money. To increase their share of outsourcing revenue, market players frequently spend on infrastructure, staff, and technology.

With the rise in cancer incidence and the creation of safe and efficient medications thanks to technical advancements, the market for oncology treatments has expanded quickly. Because of the growing demand for potent, focused medicines and the ability of compounds to be more selective towards the target of interest to reduce dosing frequencies, there is an increasing interest in highly potent New Chemical Entities (NCEs).

The pharmaceutical contract development and manufacturing market is anticipated to be dominated by North America in 2022, followed by Europe and Asia-Pacific. The substantial share of this region is primarily linked to expanding generic medicine and biologics demand, CDMO consolidation, rising need for biosimilars due to patent expiry, and rising outsourcing costs. Furthermore, the focus on pharmaceutical and biotechnology research by organisations has made the contract manufacturing business in North America extremely competitive.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Pharmaceutical Contract Development and Manufacturing Market

Report ID: SQMIG35J2034

$5,300
BUY NOW GET FREE SAMPLE